LOGO
LOGO

Earnings News

DuPont Cuts Full-year Earnings View, To Eliminate 1,500 Jobs; Shares Fall

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Chemicals giant EI DuPont de Nemours & Co. (DD), commonly called DuPont, Tuesday cut its earnings outlook for the full-year 2012 and said it plans to eliminate about 1,500 jobs as part of restructuring.

The company also reported a sharp decline in third-quarter profit, that reflected lower revenues and customer claims, as well as restructuring and impairment charges. Both earnings and sales missed analysts' expectations. The shares dropped about 7 percent in pre-market trading.

DuPont Chair and CEO Ellen Kullman said, "Weaker than expected demand in titanium dioxide and photovoltaic markets contributed to the decline from last year's record third-quarter earnings."

For the full-year 2012, DuPont now expects earnings from continuing operations, excluding significant items, in a range of $3.25 to $3.30 per share. Earlier, DuPont forecast 2012 adjusted earnings to be toward the lower end of its outlook range of $4.20 to $4.40 per share.

Analysts are currently looking for earnings of $3.93 per share for the full year. This is in comparison to last year's comparable earnings of $3.55 per share.

DuPont said it has commenced a restructuring plan, which includes elimination of about 1,500 positions globally in the next 12-18 months. The restructuring, aimed to increase productivity, enhance competitiveness and accelerate growth, is expected to save nearly $450 million, of which $300 million will be in 2013.

During the quarter, Performance Chemicals segment sales dropped 19 percent to $1.7 billion The company said its Performance Coatings business, now pending divestiture, has been reclassified and reported as discontinued operations.

Agriculture segment sales increased 4 percent, while Electronics & Communications segment sales were down 28 percent from last year. In Industrial Biosciences, sales were flat with last year and Nutrition & Health posted 4 percent increase in sales.

In the third quarter, net income attributable to the company plunged to $10 million from $452 million last year. On a per share basis, earnings were $0.01, down from $0.48 per share a year ago.

Excluding significant items, earnings per share were $0.44. In the prior year, the company had posted adjusted earnings of $0.69 per share.

On average, 14 analysts polled by Thomson Reuters expected earnings per share of $0.47 for the quarter. Analysts' estimates typically exclude one-time items.

The company posted a loss from continuing operations of $0.05 per share, compared to earnings of $0.39 per share in the prior year. Excluding significant items, earnings from continuing operations were $0.32 per share, in comparison with $0.60 per share a year ago.

Significant items in the recent quarter were customer claims charge, restructuring charge and asset impairment charge totaling $0.37 per share.

Net sales for the quarter dropped 9 percent to $7.39 billion, reflecting 5 percent lower volume, 4 percent negative currency impact and a 1 percent net reduction from portfolio changes. This was partly offset by 1 percent higher local prices. Analysts estimated revenues of $8.14 billion for the quarter.

In the pre-market activity, DuPont was trading down more than 6.75% percent. The stock had closed Monday's regular trading at $49.76 on the NYSE.

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update - Jun 01 - Jun 05, 2026

June 05, 2026 16:18 ET
A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.

Latest Updates on COVID-19